Sir,

We thank [@bib4] for their valuable and insightful comments on our study ([@bib5]) expounded in their Letter to the Editor ([@bib4]).

In our initial publication, we demonstrated the presence of the Epstein--Barr virus (EBV) in malignant breast tumours, which is consistent with findings in previous international publications ([@bib3]). In the paper, they are referring to, we observed the same positivity rate as previously noted using a more precise PCR technology. [@bib4] suggest that the positivity findings in BC specimens may have been biased by EBV-infected lymphocytes. As mentioned in our paper, our aim was to ascertain the presence of EBV in epithelial cells by isolating these cells using laser microdissection capture (LMC) ([@bib5]). A large amount of tissue (100 mg) was used to extract DNA from our specimens and this might explain why EBV was detected at a higher frequency than in other studies. In their study, Khan *et al* (2010) did not perform LMC to ensure the validity of epithelial cell positivity.

Besides, another valuable criticism leveled by Khan *et al* (2010) concerns the controversial association between EBV and BC. Other retroviruses have been reported to induce BC. In a previous report, [@bib1] induced the development of BC in an experimental model by modulating the presence of the polyoma virus during the development of the mammary gland . Moreover, the relationship between EBV and BC has been suggested in an epidemiological study ([@bib7]).

The aggressive profile of EBV-positive BC that we observed has previously been reported in other series ([@bib2]; [@bib6]). Moreover, the differentiation markers evaluated in the breast specimens are associated with the epithelial component.

Finally, we agree that EBV is a ubiquitous infection that makes the physiopathology of BC development difficult to explain. There is still a long road ahead in the field of virus-related cancer before we will be able to formally assess their role and propose prevention.
